ORG Wealth Partners LLC Acquires 57,112 Shares of Pfizer Inc. (NYSE:PFE)

ORG Wealth Partners LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2,701.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 59,226 shares of the biopharmaceutical company’s stock after buying an additional 57,112 shares during the period. ORG Wealth Partners LLC’s holdings in Pfizer were worth $1,454,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Lipe & Dalton raised its stake in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 400 shares during the period. Beam Wealth Advisors Inc. raised its stake in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after buying an additional 401 shares during the period. Providence Capital Advisors LLC raised its stake in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after buying an additional 409 shares during the period. Donaldson Capital Management LLC raised its stake in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after buying an additional 410 shares during the period. Finally, Noesis Capital Mangement Corp raised its stake in shares of Pfizer by 2.6% in the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 413 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

NYSE PFE opened at $23.88 on Thursday. The stock has a market capitalization of $135.74 billion, a PE ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57. The business has a 50 day simple moving average of $23.17 and a two-hundred day simple moving average of $24.92. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.82 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.20%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.